Fairvalue-Calculator Fairvalue-Calculator
EN DE

SynCore Biotechnology Co (4192) Fair Value & Analysis

Healthcare · TW · Market cap 740M TWD

Price21.15 TWD
Fair Value31.43 TWD
Upside+48.6%
Quality95/100
Evidence: Low Range 23.57 TWD – 39.29 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SynCore Biotechnology Co (4192) currently trades at 21.15 TWD, while our model-based Fair Value estimate is 31.43 TWD — implying the stock looks roughly 48.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

SynCore Biotechnology Co.,Ltd, engages in development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials. In addition, the company provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name such as hand-held color, hand-held monochrome, and veterinary fundus cameras that is used in recording the…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is SynCore Biotechnology Co (4192) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 31.43 TWD versus a price of 21.15 TWD — about +49% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4192?
Our 21-model fair value for SynCore Biotechnology Co is 31.43 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 21.15 TWD.
What is the quality score of 4192?
SynCore Biotechnology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.